Clinical Trial Update: Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) [Phase 1, Phase 2]

View source ↗

Summary

Biogen has withdrawn a dose-escalation Phase 1/2 trial of Baminercept in secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Baminercept (baminercept)

Snippet

Sponsor: Biogen | Conditions: Secondary Progressive Multiple Sclerosis | Phase 1, Phase 2 | Status: WITHDRAWN